Constitutive activity of human prostaglandin E receptor EP3 isoforms

British Journal of Pharmacology

Volumn 121, Issue 2, 1997, Pages 317-323

  Jin, Jianguo ^a   Mao, Guang Fen ^a   Ashby, Barrie ^a  

^a TEMPLE UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

Adenylyl cyclase; Carboxyl terminus; cDNA; Constitutive activity; Cyclic AMP; G protein; Isoforms; Prostaglandin; Prostaglandin receptor; Splice variants

Indexed keywords

ADENYLATE CYCLASE; CYCLIC AMP; FORSKOLIN; GUANINE NUCLEOTIDE BINDING PROTEIN; ISOPROTEIN; MUTANT PROTEIN; PERTUSSIS TOXIN; PROSTAGLANDIN E2; PROSTAGLANDIN RECEPTOR; PROSTAGLANDIN RECEPTOR STIMULATING AGENT; SULPROSTONE; TRITIUM;

ALTERNATIVE RNA SPLICING; ANIMAL CELL; ARTICLE; CARBOXY TERMINAL SEQUENCE; CHO CELL; CONTROLLED STUDY; DNA TRANSFECTION; ENZYME INHIBITION; NONHUMAN; NUCLEOTIDE METABOLISM; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; STRUCTURE ACTIVITY RELATION;

EID: 0030999720     PISSN: 00071188     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.bjp.0701121     Document Type: Article

References (19)

1. AN, S., YANG, J., SO, S.W., ZENG, L. & GOETZL, E.J. (1994). Isoforms of the EP3 subtype of human prostaglandin E2 receptor transduce both intracellular calcium and cAMP signals. Biochemistry, 33, 14496-14502.
2. ASHBY, B. (1990). Novel mechanism of heterologous desensitization of adenylate cyclase: Prostaglandins bind with different affinities to both stimulatory and inhibitory receptors on platelets. Mol. Pharmacol., 38, 46-53.
3. ASHBY, B. (1992). Comparison of iloprost, cicaprost and prostacyclin effects on cyclic AMP metabolism in intact platelets. Prostaglandins, 43, 255-261.
4. CHARPENTIER, S., JARVIE, K.R., SEVERYNSE, D.M., CARON, M.G. & TIBERI, M. (1996). Silencing of the constitutive activity of the dopamine DIB receptor: reciprocal mutations between D1 receptor subtypes delineate residues underlying activation properties. J. Biol. Chem., 271, 28071-28078.
5. COSTA, T., OGINA, Y., MUNSON, P.J., ONARAN, H.O. & RODBARD, D. (1992). Drug efficacy at guanine nucleotide-binding regulatory protein-linked receptors: thermodynamic interpretation of negative antagonism and of receptor activity in the absence of ligand. Mol. Pharmacol., 41, 549-560.
6. HASEGAWA, H., NEGISHI, M. & ICHIKAWA, A. (1996). Two isoforms of the prostaglandin E receptor EP3 subtype different in agonist-independent constitutive activity. J. Biol Chem., 271, 1857-1860.
7. IRIE, A., SUGIMOTO, Y., NAMBA, T., HARAZONO, A., HONDA, A., WATABE, A., NEGISHI, M., NARUMIYA, S. & ICHIKAWA, A. (1993). Third isoform of the prostaglandin E receptor EP3 subtype with different C-terminal tail coupling to both stimulation and inhibition of adenylate cyclase. Eur. J. Biochem., 217, 313-318.
8. KOTANI, M., TANAKA, I., OGAWA, Y., USUI, T., MORI, K., ICHIKAWA, A., NARUMIYA, S., YOSHIMI, T. & NAKAO, K. (1995). Molecular cloning and expression of multiple isoforms of human prostaglandin E receptor EP3 subtype generated by alternative messenger RNA splicing: multiple second messenger systems and tissue-specific distributions. Mol. Pharmacol., 48, 869-879.
9. KUNAPULI, S.P., MAO, G.F., BASTEPE, M., LIU-CHEN, L., LI, S., CHEUNG, P.P., DERIEL, J.K. & ASHBY, B. (1994). Cloning and expression of a prostaglandin E receptor EP3 subtype from human erythroleukemia cells. Biochem. J., 298, 263-267.
10. LEFKOWITZ, R.J., COTECCHIA, S., SAMAMA, P. & COSTA, T. (1993). Constitutive activity of receptors coupled to guanine nucleotide regulatory proteins. Trends Pharmacol. Sci., 14, 303-307.
11. MUNSON, P.J. & RODBARD, D. (1980). LIGAND: A versatile computerized approach for characterization of ligand-binding systems. Anal. Biochem., 107, 220-239.
12. NEGISHI, M., HASEGAWA, H. & ICHIKAWA, A. (1996). Prostaglandin E receptor EP3gamma isoform, with mostly full constitutive Gi activity and agonist-dependent Gs activity. FEBS Lett., 386, 165-168.
13. NEGISHI, M., SUGIMOTO, Y., IRIE, A., NARUMIYA, S. & ICHIKAWA, A. (1993). Two isoforms of prostaglandin E receptor EP3 subtype. Different COOH-terminal domains determine sensitivity to agonist-induced desensitization. J. Biol. Chem., 268, 9517-9521.
14. REGAN, J.W., BAILEY, T.J., DONELLO, J.E., PIERCE, K.L., PEPPERL, D.J., ZHANG, D., KEDZIE, K.M., FARBAIRN, C.E., BOGARDUS, A.M., WOODWARD, D.F. & GIL, D.W. (1994). Molecular cloning and expression of human EP3 receptors: evidence of three variants with differing carboxyl termini. Br. J. Pharmacol., 112, 377-385.
15. RIM, J. & OPRIAN, D.D. (1995). Constitutive activation of opsin: interaction of mutants with rhodopsin kinase and arrestin. Biochemistry, 34, 11938-11945.
16. SOLOMON, Y. (1979). Adenylate cyclase assay. Adv. Cyc. Nucl. Res., 10, 35-55.
17. SANGER, F., NICKLEN, S. & COULSON, A.R. (1977). DNA sequencing with chain terminating inhibitors. Proc. Natl. Acad. Sci. U.S.A., 74, 5463-5468.
18. SCHMID, A., THIERAUCH, K.-H., SCHLEUNING, W.-D. & DINTER, H. (1995). Splice variants of the human EP3 receptor for prostaglandin E2. Eur. J. Biochem., 228, 23-29.
19. ZHANG, M.-L., SUGAWA, H., KOSUGI, S. & MORI, T. (1995). Constitutive activation of the thyrotropin receptor by deletion of a portion of the extracellular domain. Biochem. Biophys. Res. Commun., 211, 205-210.